Hancock Prospecting backs Lumitron with US$50 million to scale HyperVIEW technology

Hancock Prospecting has made an initial US$50 million investment in Lumitron, with the option to lift it to US$100 million this year, to help commercialize HyperVIEW imaging and VHEE radiotherapy platforms. The deal is aimed at healthcare, mining and industrial uses, with Australia set to receive the first three systems.

Why it matters: - Hancock Prospecting’s backing gives Lumitron fresh capital to push HyperVIEW from advanced development into commercial scale-up. - The planned systems could affect cancer imaging and treatment, mineral analysis in mining, and quality control in advanced manufacturing. - Australia has secured the right to receive the first three systems, which could bring the technology to local clinical use first.

What happened: - Hancock Prospecting made an initial US$50 million investment in Lumitron on June 25, 2026. - Hancock Prospecting has the right to increase the investment to US$100 million during the 2026 calendar year. - The funding will support deployment of Lumitron’s HyperVIEW™ Very High Energy Electron beam and advanced X-ray platforms. - Hancock Prospecting nominated a representative to Lumitron’s board as part of the agreement. - Hancock also placed two members on the technical review committee, including Dr. Glenn Rice.

The details: - Lumitron says HyperVIEW is built on patented laser-Compton physics originally developed at Lawrence Livermore National Laboratory. - Dr. Rice said HyperVIEW is designed as a compact platform for ultra-high-resolution X-ray imaging and VHEE radiotherapy that can be used in existing clinical environments. - Dr. Rice said peer-reviewed studies identified HyperVIEW as the world’s highest-resolution commercial compact mono-energetic X-ray imaging machine. - Depending on configuration, the technology can deliver 100 to 1000 times greater imaging resolution than conventional X-ray systems and up to 100 times lower radiation dose. - Dr. Rice said the system is designed to improve early cancer detection and reduce healthy-tissue damage during treatment. - The U.S. Food and Drug Administration granted Breakthrough Device Designation to Lumitron’s HyperVIEW breast cancer imaging technology. - Studies in Medical Physics showed more than 3000% improvement in breast cancer imaging metrics versus leading clinical systems, according to Dr. Rice. - Research published in Frontiers in Physics showed records in laser-Compton X-ray output, high-resolution X-ray imaging, and VHEE FLASH radiotherapy capabilities. - Lumitron says it holds exclusive commercialisation rights to core intellectual property behind HyperVIEW through a licensed patent portfolio spanning more than 14 patent families. - Dr. Chris Barty said Lumitron spent nearly a decade developing the proprietary hardware and manufacturing capability needed to commercialize the platform. - The company said it is engaged with U.S. Department of Energy, DARPA, University of California, Irvine and Australia’s I-MED Radiology Network. - Hancock Prospecting said HyperVIEW could also help mining operators identify mineral composition and contaminants in ore, improving selective processing and potentially reducing energy use and costs. - Dr. Rice said future advanced manufacturing uses could include real-time detection of microscopic structural defects as small as one twentieth the width of a human hair.

Between the lines: - The investment signals that Hancock Prospecting sees Lumitron as a platform company, not just a single-product developer. - The board and technical committee appointments suggest Hancock wants influence over commercialization, not just financial exposure. - The repeated focus on healthcare and mining shows the company is pitching one core imaging platform across multiple markets to speed adoption and diversify revenue. - Some of the most aggressive performance claims come from company-linked executives and cited studies, so the commercial impact will depend on approvals, manufacturing scale-up and real-world deployment.

What's next: - Lumitron aims to produce its first commercially focused VHEE FLASH radiotherapy machine. - The company will work toward broader commercial deployment across healthcare, mining and industrial markets. - Hancock Prospecting may expand its investment to US$100 million before the end of 2026. - The company also expects eventual approval in Australia before patient use of the cancer-focused equipment.

The bottom line: - Hancock Prospecting is placing a major bet on Lumitron’s effort to turn advanced imaging and radiotherapy technology into a commercial platform with uses far beyond cancer care.